Patents by Inventor Robin L. Elliott

Robin L. Elliott has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
    Patent number: 8455629
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Grant
    Filed: January 27, 2012
    Date of Patent: June 4, 2013
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
    Patent number: 8367063
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Grant
    Filed: May 18, 2010
    Date of Patent: February 5, 2013
    Assignees: Amgen, Inc., Medarex, Inc.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
    Publication number: 20120156725
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: January 27, 2012
    Publication date: June 21, 2012
    Applicants: MEDAREX, INC., AMGEN INC.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors
    Publication number: 20110052604
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: May 18, 2010
    Publication date: March 3, 2011
    Applicant: AMGEN, INC.
    Inventors: William J. Boyle, Eugene Medlock, John J. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Human Anti-OPGL Neutralizing Antibodies As Selective OPGL Pathway Inhibitors
    Publication number: 20100209435
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: February 15, 2010
    Publication date: August 19, 2010
    Applicants: AMGEN INC., MEDAREX, INC.
    Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
    Patent number: 7718776
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Grant
    Filed: April 7, 2003
    Date of Patent: May 18, 2010
    Assignees: Amgen Inc., Medarex, Inc.
    Inventors: William J. Boyle, Eugene Medlock, John J. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
  • Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
    Publication number: 20040023313
    Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.
    Type: Application
    Filed: April 7, 2003
    Publication date: February 5, 2004
    Inventors: William J. Boyle, Eugene Medlock, John J. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang